TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Lineage Therap ( (LCTX) ) is now available.
On November 28, 2025, Lineage Cell Therapeutics withdrew its application for a CIRM Grant for the continued development of OPC1 after receiving feedback from CIRM. The company plans to address the feedback and resubmit the application in January 2026. This decision does not affect the ongoing development of OPC1 or the DOSED clinical study, which evaluates a novel device for spinal cord injury treatment.
The most recent analyst rating on (LCTX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.
Spark’s Take on LCTX Stock
According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.
Lineage Therap’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and substantial operational losses. While technical analysis shows positive momentum, and strategic partnerships offer long-term potential, the current financial challenges and negative valuation metrics weigh heavily on the stock’s attractiveness.
To see Spark’s full report on LCTX stock, click here.
More about Lineage Therap
Lineage Cell Therapeutics, Inc. operates in the biotechnology industry, focusing on regenerative medicine with a primary emphasis on developing treatments for spinal cord injuries. The company’s key product, OPC1, is designed to aid in the recovery of spinal cord injuries.
Average Trading Volume: 1,925,783
Technical Sentiment Signal: Buy
Current Market Cap: $393.9M
See more insights into LCTX stock on TipRanks’ Stock Analysis page.